CLEC2D hFc Chimera, Avi, Human
| $430.00 | |
| Z05176-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $430.00 | |
| Z05176-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 59.1 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 72-78 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of CLEC2D hFc Chimera, Avi, Human is greater than 95% as determined by SEC-HPLC. »
CLEC2D hFc Chimera, Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | C-type lectin domain family 2, member D (CLEC2D) is implicated in the immune response. Pre-eclampsia and HIV infection have opposing immune responses. The contrasting expression of CLEC2D in HIV infection and pre-eclampsia is demonstrative of the immunosuppressive and pro-inflammatory roles of the respective pathologies. However, this implication may be confounded by highly active anti-retroviral treatment (HAART). |
| Synonyms | C-type lectin domain family 2 member D;Lectin-like NK cell receptor;Lectin-like transcript 1;LLT-1;CLAX;LLT1;OCIL;CLEC2D |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.